Pathway inhibition: Emerging molecular targets for treating glioblastoma

  • Wick W
  • Weller M
  • Weiler M
 et al. 
  • 98


    Mendeley users who have this article in their library.
  • 96


    Citations of this article.


Insights into the molecular pathogenesis of glioblastoma have not yet resulted in relevant clinical improvement. With standard therapy, which consists of surgical resection with concomitant temozolomide in addition to radiotherapy followed by adjuvant temozolomide, the median duration of survival is 12-14 months. Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblastoma treatment. Recent results of bevacizumab may represent a proof of principle that treatment with targeted agents can result in clinical benefits for patients with glioblastoma. This review discusses limitations in the existing therapy for glioblastoma and provides an overview of current efforts to identify molecular targets using large-scale screening of glioblastoma cell lines and tumor samples. We discuss preclinical and clinical data for several novel molecular targets, including growth factor receptors, phosphatidylinositol-3 kinase, SRC-family kinases, integrins, and CD95 ligand and agents that inhibit these targets, including erlotinib, enzastaurin, dasatinib, sorafenib, cilengitide, AMG102, and APG101. By combining advances in tumor screening with novel targeted therapies, it is hoped that new treatment options will emerge for this challenging tumor type.

Author-supplied keywords

  • Integrins
  • PI3 kinase
  • Receptor tyrosine kinase
  • SRC-family kinases
  • VEGF signaling

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Wolfgang Wick

  • Michael Weller

  • Markus Weiler

  • Tracy Batchelor

  • Alfred W.K. Yung

  • Michael Platten

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free